Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief: Sanofi Chief Patient Officer, New Leaders At DSM, NAI And KonaRed

This article was originally published in The Tan Sheet

Executive Summary

Sanofi appoints chief patient officer; DSM names new leaders; marketing VP leaves Immunotec; Nutrition Zone names president; NAI names VP global sales; Kyowa Hakko USA hires sales manager; KonaRed appoints CFO, board member; Deloitte adds director of research.

You may also be interested in...



Gilead And Arcus’ Latest Update Keeps TIGIT Hopes Afloat

Gilead and Arcus believe their ‘Fc silent’ TIGIT inhibitor candidate could be best in class, but analysts think only outstanding results in lung cancer will sway investor sentiment.

AstraZeneca Takes Personalized Approach To Cell Therapy With Neogene Buy

The UK major has been building its cell therapy portfolio for about three years internally, oncology R&D chief Susan Galbraith tells Scrip, and the purchase of Neogene and its TCR-Ts targeting neoantigens in solid cancers is a logical step.

On-Prescription Apps Are Just One Vital Part Of Germany’s Digital Strategy

Are too few digital health care apps approved for reimbursement in Germany? That’s not the point, says the health care ministry, urging a look at the bigger strategic picture.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel